CCCandice E. Crocker

Candice E. Crocker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Candice E. Crocker has a total of 198 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cannabis related Emergency Department (ED) visits in youth: a scoping review

    by Candice E. Crocker, Ashley Francis, Chloe Hambly-LaPointe, Philip G. Tibbo

  • Open Access

    Correlates of Engagement and Associations With Outcomes in a Cannabis Harm-Reduction Mobile App for Youth With First-Episode Psychosis: Exploratory Analysis of the CHAMPS Pilot Randomized Controlled Trial

    by Amani Mahroug, Pamela Lachance-Touchette, Stéphanie Coronado-Montoya, Amal Abdel-Baki, José Côté, Candice Crocker, David Neil Crockford, Jean-Gabriel Daneault, Simon Dubreucq, Maxime Dussault-Laurendeau, et al.

    Background: Continued cannabis use among young people with first-episode psychosis (FEP) has been linked to poorer clinical and functional outcomes (eg, increased symptom severity and higher relapse rates). Digital harm-reduction interventions may represent a promising, person-centered approach to reduce at-risk cannabis use behaviors in this population. However, evidence remains limited regarding which subgroups are more likely to engage with these interventions and whether specific levels of engagement are required to achieve more favorable cannabis-related outcomes. Objective: This exploratory, hypothesis-generating analysis of the CHAMPS (Cannabis Harm-Reducing App to Manage Practices Safely) pilot randomized controlled trial (RCT) evaluated a cannabis harm-reduction mobile app for youth with FEP in early intervention services (EIS). The objectives of this study were to assess engagement by examining associations between selected sociodemographic factors and module completion and to determine whether achieving specific completion thresholds was associated with improvements in cannabis-related outcomes. Methods: Cannabis-related outcomes (Marijuana Problems Scale [MPS], Protective Behavioral Strategies for Marijuana [PBSM] scores, and days of cannabis use) were self-assessed at baseline and at week 6 (primary end point), week 12, and week 18 (postrandomization). Participants were categorized into low to moderate (0‐4 modules) and high (5‐6 modules) completion groups, and selected sociodemographic factors were compared between groups using bivariate analyses. Mixed-effects models, adjusted for baseline values and the covariates sex and cannabis use disorder (CUD) status, were fitted to evaluate whether module thresholds were associated with improvements in cannabis-related outcomes. Results: Data from 96 participants, including 46 in the CHAMPS+EIS arm and 50 in the EIS-only arm (1:1 ratio), were analyzed under a modified intention-to-treat principle. Individuals in the high-engagement group reported higher baseline social support and higher educational level ( P =.005 and P =.01). No statistically significant associations were observed between specific module completion thresholds and cannabis-related outcomes in adjusted mixed-effects models. Conclusions: Participants with higher social support and higher education were more likely to engage with CHAMPS. Although descriptive analyses suggested a potential gradient of improvement with increasing module completion, no specific completion threshold was robustly associated with improvements in outcomes. Given the multifactorial nature of engagement, supporting subgroups at risk of lower app use and examining metrics beyond module completion may enhance the impact of CHAMPS. These findings are hypothesis-generating, given their exploratory nature, and require replication in a future efficacy trial.

    • 7 July 2026
      • Vol. 12  (4) , e177
    Open Access

    Influence of cannabis potency on mental health outcomes among adolescents and young adults: scoping review.

    by Chloe Hambly Lapointe, Lilith Nosko, Candice E Crocker, Philip G Tibbo

    Recently, there has been a significant rise in potency (% tetrahydrocannabinol (THC)) of cannabis products globally. As such, there is a need for a better understanding of the relationship between cannabis potency and mental health outcomes, especially in a developmentally vulnerable population such as adolescents and young adults. The objective of this scoping review was to summarise existing literature investigating the potency of cannabis products as it relates to mental health outcomes in adolescents and young adults aged 14-25. Systematic searches of MEDLINE, Embase, CINAHL and PsycINFO were conducted for relevant manuscripts up to October 2025. Following PRISMA-ScR guidelines, retrieved studies were then screened and data extracted by two independent reviewers. Out of 11 225 studies identified by our searches, 71 were included in the review after screening. Compared with low-potency cannabis, our findings suggest that high-potency cannabis is more strongly associated with severe mental health issues, such as cannabis dependence, psychosis and cognitive deficits. Overall, it was found that high-potency cannabis use (>15% THC) was associated with a great number and magnitude of adverse mental health outcomes. As such, the potency of cannabis products should be measured in future cannabis research that investigates short- and long-term outcomes. Additionally, the potency of cannabis products should be a consideration in any future cannabis regulatory policy discussions.


  • Open Access

    Client Engagement With an Early Psychosis Program and Post‐Program Health Service Use: A Retrospective Cohort Study

    by Nathan K. Smith, Leslie Anne Campbell, Candice E. Crocker, Philip G. Tibbo

    Background: Poor engagement with Early Intervention Services (EIS) for first‐episode psychosis threatens program effectiveness, yet research often reduces engagement to a binary measure (engaged/disengaged), limiting understanding of those who disengage and re‐engage. This study examined demographics, clinical characteristics, and health service utilisation patterns among engaged, intermittently engaged, and disengaged patients of the Nova Scotia Early Psychosis Program (NSEPP). Methods: A retrospective cohort comprised of 331 individuals enrolled in NSEPP between July 22, 2005, and October 9, 2015, was constructed by linking clinical and administrative datasets. Engagement types (engaged, intermittently engaged, disengaged) were characterised in terms of baseline demographics and clinical factors, along with patterns of health service utilisation before, during, and after program enrollment. Crude and adjusted associations between program engagement and post‐program health service utilisation (emergency department (ED) use and mental health‐related hospital admissions) were assessed using negative binomial regression models. Results: During program enrollment, the intermittently engaged group had the greatest illness severity (35% spent 30+ days in hospital), and the highest proportion of individuals with at least one ED visit (85%) and one hospital admission (55%). These during‐program health service use factors were the strongest predictors of post‐program health service use outcomes. Conclusions: The three engagement types show distinct health service utilisation patterns, which may reflect differences in need, access, or program effectiveness. These results provide evidence that dichotomisation of engagement may mask important heterogeneity. Further characterisation of the engagement continuum to include intermittent engagement may provide insights to reducing barriers and improving access to and uptake of EIS.

  • Open Access

    Real-world examination of the rates of long-acting injectable attrition in a cohort of early psychosis patients after discharge from an early intervention service for psychosis

    by Candice E. Crocker, Thomas Hastings, Marc-Andre Roy, Nicola Otter, Philip G. Tibbo

    Background: Patients treated in early intervention for psychosis programs have better treatment outcomes and higher rates of long-acting injection (LAI) antipsychotic medication utilization (20%–50%) versus treatment as usual. These programs usually serve patients for 2–3 years, then most patients are discharged to other mental health services and studies of patients with longer-standing schizophrenia suggest switching to oral medications may be common. However, following patients post-discharge is complicated by the challenges of migrated patient records across clinical services and providers. Objectives: To examine whether LAI use continues after discharge from an early intervention service for psychosis. Design: This study was a retrospective cohort study examining the effects of continuation or discontinuation of LAI therapy in individuals who have completed treatment in an early intervention service (EIS) for psychosis. Methods: A retrospective cohort was created from a group of individuals discharged from EIS for psychosis over a 3-year period from January 1, 2016 to December 31, 2018 and followed for mental health outcomes and antipsychotic medications prescribed for a subsequent 2-year period at discharge, 6, 12, 18, and 24 months post-discharge. Results: Of 85 subjects discharged from three sites in three different provinces in Canada for whom full follow-up could be recorded, 60 subjects remained on LAI medications after 24 months (71%). The average age of the cohort was 22 years (SD 4.7) at admission to an EIS. At discharge, the most commonly used LAI was aripiprazole, and most subjects were maintained on the same formulation at 24 months, if still on LAI. Reasons for discontinuation were predominantly patient preference. Significant differences in clinical outcomes, measured through reduced rehospitalization were seen for those who remained on LAI as compared to those who did not. Conclusion: LAI adherence is still strong 24 months after discharge from an EIS for psychosis.


  • Open Access

    Understanding the role of cannabis in patients with suicidal ideation presenting to the emergency department: systematic chart review

    by Maria Simmons, Candice E. Crocker, Derek Fisher, Sherry H. Stewart, Jason G. Emsley, Sabina Abidi, Alix Carter, Cynthia Calkin, Igor Yakovenko, Kirk Magee, et al.

    Background: The association between cannabis use and suicidality has been established, but details on impacts of legalisation, as well as long-term service use, have had limited attention. Aims: To examine if changes are present in suicide presentations with access to legal cannabis. Method: This study employed administrative database and medical record reviews to identify two cohorts of patients presenting with suicidal ideation/attempts and cannabis use to emergency departments, for two periods: 17 October 2018 to 30 April 2019, and 17 October 2020 to 30 April 2021. Demographic and clinical outcome data were obtained, and emergency department healthcare usage for 2 years before and 2 years after index encounter were compared, to further understand emergency department presentations for the same complaint. Results: Number of emergency department encounters following the index visit and number of emergency department encounters specifically relating to suicidality following the index visit were significantly different between cohorts (t = 2.05, P = 0.042; t = 2.23, P = 0.027, respectively), with the immediate post-cannabis legalisation period demonstrating greater numbers of subsequent emergency department visits for suicidality. Additional associations were found between personality disorders and repeat emergency department visits related to cannabis use. Conclusions: There appears to be stability in the patient profile of those presenting to the emergency department with a complaint relating to suicide while reporting cannabis use from the period directly following legalisation in Canada, to a similar time frame 2 years later despite reported increased use of cannabis in the general population over this period. Despite the rising potency and access to legal cannabis, suicide risk remains stable, although concerning.


  • Open Access

    A pilot randomized controlled trial of a digital cannabis harm reduction intervention for young adults with first-episode psychosis who use cannabis

    by Stephanie Coronado-Montoya, Amal Abdel-Baki, Paule Bodson-Clermont, David Boucher-Roy, José Côté, Candice E. Crocker, David Crockford, Jean-Gabriel Daneault, Simon Dubreucq, Maxime Dussault-Laurendeau, et al.


  • Open Access

    Mental health adverse events with cannabis use diagnosed in the Emergency Department: what are we finding now and are our findings accurate?

    by Candice E. Crocker, Jason Emsley, Philip G. Tibbo

    We have previously reviewed the types and numbers of cannabis-associated adverse events that have mental health presentations that are encountered in the Emergency Department. A particular challenge in examining these events is disentangling cannabis use adverse events from adverse events associated with use of multiple recreational substances. Since that review was published, cannabis legalization for recreational use has greatly expanded world-wide and with these changes in the legal climate has come clearer information around the frequency of adverse events seen in the Emergency Department. However, as we examined the current state of the literature, we also examined some of research designs and the biases that may be impacting the validity of the data in this field. The biases both of clinicians and researchers as well as research approaches to studying these events may be impacting our ability to assess the interaction between cannabis and mental health. For example, many of the studies performed examining cannabis-related admissions to the Emergency Department were administrative studies that relied on front line clinicians to identify and attribute that cannabis use was associated with any particular admission. This narrative review provides an overview on what we currently know about mental health adverse events in the Emergency Department with a focus on the mental health impacts both for those with and without a history of mental illness. The evidence that cannabis use can adversely impact genders and sexes differently is also discussed. This review outlines what the most common adverse events related to mental health with cannabis use are; as well as noting the most concerning but much rarer events that have been reported. Additionally, this review suggests a framework for critical evaluation of this field of study going forward.


  • Open Access

    Examination of the impact of COVID-19 public health quarantine measures on acute mental health care services: A retrospective observational study

    by Nadine Nejati, Candice Crocker, Miroslava Kolajova, Jason Morrison, Patryk Simon, Sanjana Sridharan, Philip Tibbo